Quality assurance of the EORTC 22043-30041 trial in post-operative radiotherapy in prostate cancer: Results of the Dummy Run procedure

被引:16
作者
Fenton, Paul A. [1 ,2 ]
Hurkmans, Coen [3 ]
Gulyban, Akos [1 ]
van der Leer, Jorien [3 ]
Matzinger, Oscar [1 ,4 ]
Poortmans, Philip [5 ]
Collette, Laurence [1 ]
Bolla, Michel [6 ]
机构
[1] EORTC Headquarters, Brussels, Belgium
[2] Southampton Univ Hosp, Dept Radiotherapy, Southampton SO16 6YD, Hants, England
[3] Catharina Hosp, Dept Radiat Oncol, Eindhoven, Netherlands
[4] CHU Vaudois, Dept Radiat Oncol, CH-1011 Lausanne, Switzerland
[5] Inst Verbeeten, Dept Radiat Oncol, Tilburg, Netherlands
[6] CHR Univ Grenoble, Grenoble, France
关键词
Radiotherapy; Quality assurance; Prostate; Dummy Run; Delineation; TARGET VOLUME DEFINITION; RADIATION-THERAPY; PHASE-III; CONSENSUS GUIDELINES; ADVANCED TECHNOLOGY; COOPERATIVE GROUP; VARIABILITY; IMPACT; BED;
D O I
10.1016/j.radonc.2013.04.020
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Background and purpose: The EORTC 22043-30041 trial investigates the role of the addition of androgen suppression to post-operative radiotherapy in patients who have undergone radical prostatectomy. As part of the quality assurance of radiotherapy (QART) a Dummy Run (DR) procedure was performed. Materials and method: The protocol included detailed and published delineation guidelines. Participating institutions digitally submitted radiotherapy treatment volumes and a treatment plan for a standard clinical case. Submissions were centrally reviewed using the VODCA software platform. Results: Thirty-eight submissions from thirty-one institutions were reviewed. Six were accepted without comments. Twenty-three were accepted with comments on one or more items: target volume delineation (22), OAR delineation (23), planning and dosimetry (3) or treatment verification (1). Nine submissions were rejected requiring resubmission, seven for target volume delineation reasons alone. Intervention to highlight the importance of delineation guidelines was made prior to the entry of the first patient in the trial. After this, a lower percentage of resubmissions was required. Conclusions: The EORTC 22043-30041 Dummy Run highlights the need for timely and effective QART in clinical trials. The variation in target volume and OAR definition demonstrates that clinical guidelines and radiotherapy protocols are not a substitute for QART procedures. Early intervention in response to the Dummy Run improved protocol understanding. (c) 2013 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:346 / 351
页数:6
相关论文
共 34 条
[1]
High conformality radiotherapy in Europe: thirty-one centres participating in the quality assurance programme of the EORTC prostate trial 22991 [J].
Ataman, F ;
Poortmans, P ;
Davis, JB ;
Bernier, J ;
Giraud, JY ;
Kouloulias, VE ;
Pierart, M ;
Bolla, M .
EUROPEAN JOURNAL OF CANCER, 2004, 40 (16) :2411-2416
[2]
Quality assurance of the EORTC 26981/22981; NCICCE3 intergroup trial on radiotherapy with or without temozolomide for newly-diagnosed glioblastoma multiforme: the individual case review [J].
Ataman, F ;
Poortmans, P ;
Stupp, R ;
Fisher, B ;
Mirimanoff, RO .
EUROPEAN JOURNAL OF CANCER, 2004, 40 (11) :1724-1730
[3]
Guidelines for primary radiotherapy of patients with prostate cancer [J].
Boehmer, Dirk ;
Maingon, Philippe ;
Poortmans, Philip ;
Baron, Marie-Helene ;
Miralbell, Raymond ;
Remouchamps, Vincent ;
Scrase, Christopher ;
Bossi, Alberto ;
Bolla, Michel .
RADIOTHERAPY AND ONCOLOGY, 2006, 79 (03) :259-269
[4]
Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin [J].
Bolla, M ;
Gonzalez, D ;
Warde, P ;
Dubois, JB ;
Mirimanoff, RO ;
Storme, G ;
Bernier, J ;
Kuten, A ;
Sternberg, C ;
Gil, T ;
Collette, L ;
Pierart, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (05) :295-300
[5]
Postoperative radiotherapy after radical prostatectomy:: a randomised controlled trial (EORTC trial 22911) [J].
Bolla, M ;
van Poppel, H ;
Collette, L ;
van Cangh, P ;
Vekemans, K ;
Da Pozzo, L ;
de Reijke, TM ;
Verbaeys, A ;
Bosset, JF ;
van Velthoven, R ;
Maréchal, JM ;
Scalliet, P ;
Haustermans, K ;
Piérart, M .
LANCET, 2005, 366 (9485) :572-578
[6]
Duration of Androgen Suppression in the Treatment of Prostate Cancer [J].
Bolla, Michel ;
de Reijke, Theodorus M. ;
Van Tienhoven, Geertjan ;
Van den Bergh, Alphonsus C. M. ;
Oddens, Jorg ;
Poortmans, Philip M. P. ;
Gez, Eliahu ;
Kil, Paul ;
Akdas, Atif ;
Soete, Guy ;
Kariakine, Oleg ;
Van der Steen-Banasik, Elsbietha M. ;
Musat, Elena ;
Pierart, Marianne ;
Mauer, Murielle E. ;
Collette, Laurence .
NEW ENGLAND JOURNAL OF MEDICINE, 2009, 360 (24) :2516-2527
[7]
Profile of European radiotherapy departments contributing to the EORTC Radiation Oncology Group (ROG) in the 21st century [J].
Budiharto, Tom ;
Musat, Elena ;
Poortmans, Philip ;
Hurkmans, Coen ;
Monti, Angelo ;
Bar-Deroma, Raquel ;
Bernstein, Zvi ;
van Tienhoven, Geertjan ;
Collette, Laurence ;
Duclos, Frederic ;
Davis, Bernard ;
Aird, Edwin .
RADIOTHERAPY AND ONCOLOGY, 2008, 88 (03) :403-410
[8]
Interphysician variability in defining the planning target volume in the irradiation of prostate and seminal vesicles [J].
Cazzaniga, LF ;
Marinoni, MA ;
Bossi, A ;
Bianchi, E ;
Cagna, E ;
Cosentino, D ;
Scandolaro, L ;
Valli, M ;
Frigerio, M .
RADIOTHERAPY AND ONCOLOGY, 1998, 47 (03) :293-296
[9]
Quality assurance of the EORTC trial 22911. A phase III study of post-operative external radiotherapy in pathological stage T3NO prostatic carcinoma: the dummy run [J].
Davis, JB ;
Reiner, B ;
Dusserre, A ;
Giraud, JY ;
Bolla, M .
RADIOTHERAPY AND ONCOLOGY, 2002, 64 (01) :65-73
[10]
QUALITY ASSURANCE OF THE EORTC RADIOTHERAPY TRIAL-22863 FOR PROSTATIC-CANCER - THE DUMMY RUN [J].
DUSSERRE, A ;
GARAVAGLIA, G ;
GIRAUD, JY ;
BOLLA, M .
RADIOTHERAPY AND ONCOLOGY, 1995, 36 (03) :229-234